Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

@article{Jadzinsky2009SaxagliptinGI,
  title={Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.},
  author={Mauricio N Jadzinsky and Andreas Pf{\"u}tzner and Elizabeth Paz-Pacheco and Z Xu and Elsie Allen and Riqiu Chen},
  journal={Diabetes, obesity & metabolism},
  year={2009},
  volume={11 6},
  pages={
          611-22
        }
}
AIM The study aim was to evaluate the efficacy and safety of initial combination therapy with saxagliptin + metformin vs. saxagliptin or metformin monotherapy in treatment-naïve patients with type 2 diabetes (T2D) and inadequate glycaemic control. METHODS In this multicentre, randomized, double-blind, active-controlled phase 3 trial, 1306 treatment-naïve patients with T2D >or=18 to <or=77 years, glycosylated haemoglobin (HbA1c) >or=8 to <or=12%, fasting C-peptide concentration >or=1.0 ng/ml… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 159 CITATIONS, ESTIMATED 40% COVERAGE

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety

  • Advances in Therapy
  • 2015
VIEW 14 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2010
VIEW 5 EXCERPTS
CITES RESULTS, BACKGROUND & METHODS
HIGHLY INFLUENCED

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin

  • Diabetes, metabolic syndrome and obesity : targets and therapy
  • 2017
VIEW 4 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies.

  • Journal of managed care pharmacy : JMCP
  • 2014
VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Saxagliptin overview: special focus on safety and adverse effects.

  • Expert opinion on drug safety
  • 2013
VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2009
2018

CITATION STATISTICS

  • 19 Highly Influenced Citations

  • Averaged 8 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Clinical practice guidelines for the prevention and management of diabetes in Canada

DM Nathan, JB Buse, MB Davidson
  • Can J Diabetes
  • 2008

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.

  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2007